Skip to main content
Log in

The tolerance to and pharmacokinetics of penciclovir (BRL 39123A), a novel antiherpes agent, administered by intravenous infusion to healthy subjects

European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The tolerance to and pharmacokinetics of intravenously administered penciclovir (BRL 39123A), a novel anti-herpes agent, were investigated in 15 healthy male subjects. The volunteers were divided into three groups, receiving either 10, 15 or 20 mg/kg penciclovir by a 60 min constant-rate infusion. Blood samples were taken sequentially up to 48 h after the start of the infusion and urine collections made at appropriate intervals up to 72 h. After a simple solid phase extraction, concentrations of penciclovir in plasma and urine were determined using HPLC with U. V detection.

Mean values of Cmax, corresponding usually with the end of infusion, and of AUC appeared to increase proportionately with dose. Furthermore, there was no evidence that dose significantly affected any individual pharmacokinetic parameter.

Penciclovir was distributed into tissues with an overall mean volume of distribution of approximately 1.51 · kg−1, i. e. approximately double that of body water. It was rapidly eliminated, with a mean total plasma clearance of 39.31 · h−1, and a mean terminal-phase half-life of 2.0 h. The majority of the dose, approximately 70%, was excreted unchanged in the urine. Mean renal clearance of BRL 39123 was 28.1 1 · h−1, which exceeds normal glomerular filtration rate and approaches renal plasma flow.

At all dose-levels, the infusions of penciclovir were well tolerated, with no evidence of drug-related adverse events.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Boyd MR, Bacon TH, Sutton D, Cole M (1987) Antiherpesvirus Activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl) guanine (BRL 39123) in cell culture. Antimicrob Agents Chemother31: 1238–1242

    Google Scholar 

  2. Boyd MR, Bacon TH, Sutton D (1988) Antiherpesvirus Activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl) guanine (BRL 39123) in animals. Antimicrob Agents Chemother32:358–363

    Google Scholar 

  3. Vere Hodge TA, Perkins RM (1989) Mode of action of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl) guanine (BRL 39123) against Herpes simplex virus in MRC-5 cells. Antimicrob Agents Chemother33: 223–229

    Google Scholar 

  4. Fowles SE, Pierce DM, Prince WT, Staniforth D (1989) The pharmacokinetics of BL 39123A, a novel anti-herpes agent, administered by intravenous infusion to healthy subjects at doselevels of 10, 15 and 20 mg kg−1. Br J Clin Pharmacol28: 236P-237P

    Google Scholar 

  5. Fowles SE, Pierce DM (1989) HPLC method for the determination of BRL 39123 in human plasma and urine. Analyst114: 1373–1375

    Google Scholar 

  6. Allen GD (1990) MODFIT: a pharmacokinetics computer program. Biopharm Drug Dispos11: 477–498

    Google Scholar 

  7. Gibaldi M, Perrier D (1982) Pharmacokinetics. Dekker, New York

    Google Scholar 

  8. Remingtons Pharmaceuticals Sciences (1985) 17th edn. Mack Publishing Company, Euston, Pennsylvania

  9. De Miranda P, Whitley RJ, Blum MR, Keeney RE, Barton N, Cocchetto DM, Good S, Hemstreet GP, Kirk LE, Page DA, Elion GB (1979) Acyclovir kinetics after intravenous infusion. Clin Pharmacol Ther 26:718–728

    Google Scholar 

  10. Laskin OL, De Miranda P, King DH, Page DA, Longstreth JA, Rocco L, Lietman PS (1982a) Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. Antimicrob Agents Chemother 21: 804–807

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fowled, S.E., Pierce, D.M., Prince, W.T. et al. The tolerance to and pharmacokinetics of penciclovir (BRL 39123A), a novel antiherpes agent, administered by intravenous infusion to healthy subjects. Eur J Clin Pharmacol 43, 513–516 (1992). https://doi.org/10.1007/BF02285093

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02285093

Key words

Navigation